Maternal and neonatal outcomes in obstetric antiphospholipid syndrome: a retrospective case-control study.

Objective: The combination of low-dose aspirin (LDA) and low-molecular-weight heparin (LMWH) is the standard of care for obstetric antiphospholipid syndrome (OAPS), significantly improving live birth rates. However, whether this regimen fully normalizes the pregnancy course and mitigates risks for both the mother and the neonate remains unclear. This study aimed to systematically evaluate whether significant maternal and neonatal morbidity persists in OAPS patients despite successful treatment and live birth. Methods: This retrospective cohort study included 256 OAPS patients, including 166 criteria OAPS patients (C-OAPS-patients who fulfilled both the clinical and laboratory criteria of the Sydney criteria) and 90 non-criteria OAPS patients (NC-OAPS-patients who fulfilled only the clinical or only the laboratory criteria of the Sydney criteria) who achieved live birth, along with 768 matched healthy controls. We compared basic characteristics, laboratory parameters, and perinatal outcomes between the groups. Results: Compared to healthy controls ( Conclusion: Despite standard treatment, OAPS patients who deliver successfully remain at an increased risk for persistent maternal hypercoagulability and adverse neonatal outcomes. These findings underscore the need for a paradigm shift in management-from merely ensuring live birth to safeguarding neonatal health through proactive, multidisciplinary perinatal care.